Detalles de la búsqueda
1.
Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.
Cell
; 154(3): 556-68, 2013 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23911321
2.
A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates.
BJU Int
; 2024 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38837608
3.
Transcriptomic analysis of plasma exosomes provides molecular information of response to cabazitaxel treatment in men with metastatic castration-resistant prostate cancer.
Prostate
; 83(10): 950-961, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37074030
4.
Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort.
J Urol
; 206(5): 1147-1156, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34503355
5.
Mitochondrial DNA copy number in peripheral blood leukocytes is associated with biochemical recurrence in prostate cancer patients in African Americans.
Carcinogenesis
; 41(3): 267-273, 2020 05 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-31408512
6.
Genetic variants in epithelial-mesenchymal transition genes as predictors of clinical outcomes in localized prostate cancer.
Carcinogenesis
; 41(8): 1057-1064, 2020 08 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32215555
7.
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
Lancet Oncol
; 20(10): 1432-1443, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31515154
8.
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
Proc Natl Acad Sci U S A
; 113(42): 11919-11924, 2016 10 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-27698113
9.
Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.
Proc Natl Acad Sci U S A
; 113(45): 12786-12791, 2016 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27791181
10.
Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer.
Proc Natl Acad Sci U S A
; 112(8): 2515-20, 2015 Feb 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-25675522
11.
Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors.
Proc Natl Acad Sci U S A
; 112(12): 3776-81, 2015 Mar 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-25762070
12.
PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3.
Proc Natl Acad Sci U S A
; 112(27): 8403-8, 2015 Jul 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26080435
13.
Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance.
Carcinogenesis
; 37(10): 965-971, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27515962
14.
Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer.
Cancer
; 122(12): 1836-43, 2016 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27018785
15.
Abiraterone in metastatic prostate cancer without previous chemotherapy.
N Engl J Med
; 368(2): 138-48, 2013 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-23228172
16.
17.
The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study.
BMC Cancer
; 16: 721, 2016 09 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27599544
18.
Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance.
BJU Int
; 117(3): 469-77, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25714186
19.
Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance.
BJU Int
; 118(1): 68-76, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26059275
20.
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Lancet Oncol
; 16(2): 152-60, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25601341